SCHEMBL6030376

SCHEMBL6030376

CCCCCCCOC(=O)Nc1sc(C(=O)OCCCCCCC)c(C)c1C(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.52
ALDH1A1 P00352 14/20 0.48
TSHR P16473 6/20 0.48
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HPGD P15428 5/20 0.46
HSD17B10 Q99714 6/20 0.46
NPSR1 Q6W5P4 2/20 0.46
SMN1; SMN2 Q16637 3/20 0.43
MAPK1 P28482 2/20 0.43
MAPT P10636 3/20 0.43
DUSP3 P51452 1/20 0.42
PTPN5 P54829 1/20 0.42
PTPN11 Q06124 1/20 0.42
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030718 1.00 PKM (0.52) PKMALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL6030976 0.92 PKM (0.47) PKMALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL6030676 0.91 PKM (0.47) PKMALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL6030375 0.88 MAPT (0.45) PKMALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL6030720 0.88 PKM (0.43) PKMALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL6030380 0.88 PKM (0.43) PKMALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL6030349 0.87 ALDH1A1 (0.47) PKMALDH1A1TSHRHPGDHSD17B10
SCHEMBL6030337 0.86 CNR1 (0.44) PKMALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL6030952 0.86 CNR1 (0.44) PKMALDH1A1TSHRCYP1A2CYP2C9
SCHEMBL6030914 0.81 MAPT (0.61) ALDH1A1TSHRHPGDHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL PKM 4066/4885ALDH1A1 1832/4885TSHR 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.